Minhai COVID-19 vaccine
Vaccine description
TargetSARS-CoV-2
Vaccine typeInactivated
Clinical data
Other namesKCONVAC (Chinese: 可维克; pinyin: Kěwéikè)
Routes of
administration		Intramuscular
Legal status
Legal status
Part of a series on the
COVID-19 pandemic
Scientifically accurate atomic model of the external structure of SARS-CoV-2. Each "ball" is an atom.
Scientifically accurate atomic model of the external structure of SARS-CoV-2. Each "ball" is an atom.
Timeline
2019
2020
2021
2022
2023
2024
Locations
By country and territory
By conveyance
International response
National responses
Medical response
Vaccines
Current vaccines
Variants
Variants of concern
Other variants
Economic impact and recession
By country
By sport
Impacts
Society
virus icon COVID-19 portal

Minhai COVID-19 vaccine (Chinese: 康泰民海新冠疫苗), trademarked as KCONVAC (Chinese: 可维克; pinyin: Kěwéikè), is a COVID-19 vaccine developed by Shenzhen Kangtai Biological Products Co. Ltd and its subsidiary, Beijing Minhai Biotechnology Co., Ltd.

Clinical trials

In October 2020, KCONVAC started phase I clinical trials with 180 participants in China.[1] Later, KCONVAC started phase II trials with 1,000 participants in China.[2]

In May 2021, KCONVAC started phase III trials for global trials with 28,000 participants.[3]

Children and adolescents trials

In August 2021, KCONVAC started phase I trials with 84 participants in China.[4]

In September, KCONVAC started phase II trials with 480 participants in China.[5]

Authorizations

Graphs are unavailable due to technical issues. There is more info on Phabricator and on MediaWiki.org.
  Full authorization
  Emergency authorization
  Allowed for travel

See also: List of COVID-19 vaccine authorizations § Minhai

On 14 May 2021, the vaccine became the fourth inactivated Chinese Vaccine to be authorised for emergency use.[6]

References

  1. ^ Clinical trial number NCT04756323 for "A Study to Evaluate Safety and Immunogenicity of Inactivated SARS-CoV-2 Vaccine (Vero Cells) in Healthy Population Aged 18 Years and Above(COVID-19) " at ClinicalTrials.gov
  2. ^ Clinical trial number NCT04758273 for "A Safety and Immunogenicity Study of Inactivated SARS-CoV-2 Vaccine (Vero Cells) in Healthy Population Aged 18 Years and Above(COVID-19)" at ClinicalTrials.gov
  3. ^ Clinical trial number NCT04852705 for "A Study to Evaluate the Efficacy, Safety and Immunogenicity of SARS-CoV-2 Vaccine (Vero Cells), Inactivated in Healthy Adults Aged 18 Years and Older (COVID-19)" at ClinicalTrials.gov
  4. ^ Clinical trial number NCT05003479 for "A Phase I Clinical Trial of SARS-CoV-2 Vaccine (Vero Cells), Inactivated in Healthy Population Aged 3 to 17 Years (COVID-19)" at ClinicalTrials.gov
  5. ^ Clinical trial number NCT05003466 for "A Phase II Clinical Trial of SARS-CoV-2 Vaccine (Vero Cells), Inactivated in Healthy Population Aged 3 to 17 Years (COVID-19)" at ClinicalTrials.gov
  6. ^ "Kangtai Biological's COVID-19 vaccine gets emergency use approval in China". Reuters. 14 May 2021. Retrieved 20 May 2021.
Scholia has a profile for Minhai COVID-19 vaccine (Q106522079).


Categories